Here, we induced genetic recombination in villin-creERT2 Krasfl/G12D or villin-creERT2 Kras+/G12D mice, and assessed survival based upon sampling due to onset clinical signs associated with significant intestinal tumour burden. Here, KRAS is linked to intestinal neoplasm.